Agnes Charles-Torres
Hematology & Oncology · San Juan, PRNPI 1639166689
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,008 of the $3,490 with a category attached, or 86.2%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,162 and has fallen 62.9% since, to $431 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PR, where the typical reported total is $10,882.
Across 145 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$544
- Merck$408
- Sanofi$232
- Bayer$230
- Astellas Pharma US Inc$207
- E.r. Squibb & Sons, L.L.C.$193
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,00886%
- Education$48214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 17 | $544 |
| Merck | 30 | $408 |
| Sanofi | 5 | $232 |
| Bayer | 7 | $230 |
| Astellas Pharma US Inc | 9 | $207 |
| E.r. Squibb & Sons, L.L.C. | 8 | $193 |
| Lilly USA, LLC | 4 | $159 |
| Amgen | 8 | $149 |
| AstraZeneca(2 entities) | 8 | $148 |
| Seagen Inc. | 2 | $125 |
| Tersera Therapeutics LLC | 5 | $102 |
| Incyte Corporation | 2 | $100 |
| Novartis | 4 | $100 |
| Agios Pharmaceuticals, Inc. | 1 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Pfizer | 3 | $61 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Myriad Genetic Laboratories, Inc. | 2 | $51 |
| Blue Earth Diagnostics | 2 | $51 |
| Bristol Myers Squibb | 2 | $47 |
| Myovant Sciences Inc. | 2 | $44 |
| AMAG Pharmaceuticals, Inc. | 3 | $43 |
| Exelixis Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Sobi, Inc | 1 | $29 |
| Gilead(2 entities) | 2 | $27 |
| Dova Pharmaceuticals | 1 | $24 |
| Tesaro, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Epizyme, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,490 in reported general payments places this provider in the 30th percentile of 138 hematology & oncology providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 26 | $381,941 |
| NubeqaDarolutamide | 18 | $199,544 |
| XareltoRivaroxaban | 15 | $16,178 |
| Sucralfate | 14 | $3,297 |
| Esomeprazole Magnesium | 25 | $1,646 |
| Potassium Chloride | 51 | $1,627 |
| Exemestane | 12 | $866 |
| Dexamethasone | 43 | $843 |
| Gabapentin | 44 | $721 |
| Hydroxyurea | 21 | $686 |
| Rosuvastatin Calcium | 23 | $647 |
| Ondansetron OdtOndansetron | 35 | $646 |
| Ibandronate Sodium | 11 | $595 |
| Anastrozole | 30 | $521 |
| Levothyroxine Sodium | 55 | $453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $544 | $398,11941 claims |
| BayerNubeqa | $230 | $199,54418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in San Juan
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Mirelis AcostaSan Juan$154K
- Luis Baez VallecilloSan Juan$107K
- Edgardo Santiago-GuzmanSan Juan$79K
- Adelba Torres-LopezSan Juan$73K
- Karla Feliciano SalvaSan Juan$44K
- Luis Delgado MateuSan Juan$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.